Bernstein analyst William Pickering upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Advances Suzetrigine Phase 3 Trial in Diabetic Nerve Pain, Signaling a Broader Growth Story
- Sionna Therapeutics price target raised to $58 from $50 at BTIG
- Vertex Pharmaceuticals assumed with a Buy at UBS
- Wolfe upgrades Vertex Pharmaceuticals, says ‘may be due for a rebound’
- Vertex Pharmaceuticals upgraded to Outperform from Peer Perform at Wolfe Research